INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 450m ago
HOUSE PTR50m ago
SEC 13F50m ago
ROBINHOOD CHAIN50m ago
SEC FORM 4/Grant or awardVerified data

Feuchtwang Ilan reported CTKB

Chief Legal Officer, Secretary · Cytek Biosciences, Inc. · Cytek Biosciences, Inc. — Restricted Stock Units

Side
A
Value
—
Shares
241.4K
Price
—
Executed
Aug 10, 2026
Disclosed
Aug 12, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Aug 10 executedAug 12, 2026 disclosed

CTKB · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CTKB

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    6,320 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$9,858
    2,111 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$33K
    7,062 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    29.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    13.1K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    7,363 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$7,010
    1,501 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$6,286
    1,346 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    6,162 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$25K
    5,382 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    11.8K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    57.2K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JW
    Jiang WenbinDirector, PRESIDENT AND CEO
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    22.1K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$8,303
    1,778 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$25K
    5,401 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    16.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MD
    McCombe William D.Chief Financial Officer
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    16.0K sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    5,525 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Tax withholding
    		F$16K
    3,463 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    21
    YM
    Yan MingDirector, CHIEF TECHNOLOGY OFFICER
    CTKBCytek Biosciences, Inc.
    Option exercise
    		M—
    7,363 sh
    		Aug 18, 2026Aug 20, 2026
    traded Aug 18, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002141966-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 10, 2026
    Published
    Aug 12, 2026
    Ingested by INSIDER
    Nov 5, 02:23 UTC
    Last re-read
    Nov 5, 02:23 UTC

    Extracted facts

    Filer
    Feuchtwang Ilan
    Role
    Chief Legal Officer, Secretary
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Cytek Biosciences, Inc. — Restricted Stock Units
    Ticker
    CTKB
    Shares
    241.4K
    Price per share
    $0
    Execution date (reported)
    Aug 10, 2026
    Owned after transaction
    241.4K shares
    Days from execution to publication
    2

    What this establishes

    Feuchtwang Ilan filed this Form 4 reporting a grant or award of CTKB on Aug 10, 2026. It became public on Aug 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Legal Officer, Secretary
    Feuchtwang Ilancik:0002141966
    Issuer
    Cytek Biosciences, Inc.cik:0001831915

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.